Tuesday, August 4, 2015

PhillyInc plants the seed that DuPont is raising 2011 guidance

The Wilmington chemical giant reported higher sales and profits for its second quarter and boosted its earnings forecast for the rest of the year.

PhillyInc plants the seed that DuPont is raising 2011 guidance

0 comments

DuPont raised its earnings guidance for the rest of 2011 to $3.90 to $4.50 (excluding items) from $3.65 to $3.85. The Wilmington chemical giant reports strong sales for its biotech seeds and paint pigment. Q2 earnings per share of $1.37 were up 17 percent compared with $1.17 per share last year.

Revenues for DuPont climbed to $10.5B from $9.1B for the 2d qtr. of 2010. The company says it will now report results with two new business segments: Industrial Biosciecnes (following its acquisition of Danisco) and Nutrition & Health (which was broken out from its previous Agriculture & Nutrition unit).

AmerisourceBergen's new CEO, Steven Collis, got to deliver good news in his first earnings announcement. The Valley Forge-based wholesale drug distributor squeezed out a 2.9 percent rise in revenue to $20.2B for its Q3. Net income of $184.4M, or 66 cents per share, increased by 13 percent.

Airgas reported higher profits for its Q1 ended June 30. The Radnor-based distributor of industrial and medical gases had net income of $74.8M, or 93 cents per share, vs. $64.8M, or 76 cents per share. Net sales were up slightly to $1.16B.

Here's what CEO Peter McCausland had to say:

Although more than a year old, the economic recovery has been slow, and the strength displayed in manufacturing-intensive regions of the U.S. and in our hardgoods business is indicative of the early stages of a recovery.

Also, Exton's ViroPharma reported lower net income for its Q2 - $22.8M, or 28 cents per share, vs. $28.5M, or 34 cents per share. The maker of Cinryze and Vancocin did see net sales rise to $128.8M from $109.0M.

Inquirer Columnist
0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
Mike Armstrong blogs about Philadelphia corporations and business-related topics. Contact him at 215-854-2980. Reach Mike at marmstrong@phillynews.com.

Mike Armstrong Inquirer Columnist
Also on Philly.com:
letter icon Newsletter